We split patients in the training cohort in five groups, according to the tumor BCL6, CD11c, BCL2, and LAIR1 expression (high/low), and then performed Kaplan Meier analyses to determine the overall survival (OS) in the function of the expression level. This evidence concerns the gene BCL2 and neoplasm.